Telomere dysfunction-induced loss of genome integrity and its associated DNA damage signaling and checkpoint responses are well-established drivers that cause tissue degeneration during ageing. Cancer, with incidence rates greatly increasing with age, is characterized by short telomere lengths and high telomerase activity. To study the roles of telomere dysfunction and telomerase reactivation in ageing and cancer, the protocol shows how to generate two murine inducible telomerase knock-
Introduction
Telomerase is an enzyme responsible for maintaining telomeres. These are repetitive sequences at the ends of chromosomes that protect their integrity. The core components of telomerase holoenzyme are a reverse transcriptase catalytic subunit (TERT) and an RNA subunit (TERC) that serves as the template for adding the telomeric repeats 1, 2 . While generally suppressed in differentiated somatic cells, telomerase exhibits robust activity and plays important roles in germ cells, cancer cells and stem cells. mTERC and mTERT knockout mice provide great in vivo model systems to study the functions of telomerase in both stem cells and cancer. The mTERC and mTERT knockout mice (G1) did not show any obvious phenotypes due to the long reserve of telomeres in mice 3 . However, serially intercrossing mTERC and mTERT knockout mice to late generation (G5-G6) resulted in progressive erosion of telomeres and eventually provoked severe degeneration of highly proliferative tissues 4 . Late generation (G5-G6) mTERC -/-mice are infertile due to the high rates of apoptosis in testis and germ cell depletion. G5-G6 mTERC -/-mice also exhibit degenerative phenotypes in highly proliferative tissues including bone marrow, intestine and skin due to high rates of apoptosis and defective self-renewal capability in tissue stem/progenitor cell compartments 4 . Hematopoietic stem cells in the bone marrow of late generation mTERC -/-mice exhibit loss of proliferative potential, compromised self-renewal capability, enhanced apoptosis and, eventually functional exhaustion 5, 6 . Similarly, progressively increased apoptotic bodies in intestinal crypts were observed in each successive generation of G1-G6 mTERC -/-mice 7, 8 . The deleterious effect of dysfunctional telomeres doesn't seem to be limited to high turnover tissues since both the proliferation of adult neural stem cells in vitro and the neurogenesis in vivo were severely impaired in late generation (G4-G5) mTERC -/-mice 9 . The role of telomerase in stem cells is further supported by the findings in a rare human genetic disorder dyskeratosis congenita (DKC), which in some ways resembles premature ageing 10, 11 . DKC is caused by mutations in TERC, TERT, and genes that encode dyskerin, a core telomerase subunit, and other dyskerin associated proteins 12 . In average, telomeres in DKC patients are shorter than 99% of age-matched controls. The major morbidity of the disease is due to aplastic anemia, which is caused by defective maintenance of hematopoietic stem cells. Other aspects of the disease such as oral leukoplakia, nail dystrophy, mental retardation, testes atrophy and pulmonary complications all suggest impaired functions of tissue stem cells and progenitor cells those in late generation of telomerase knockout mice. DKC patients are prone to myelodysplastic syndrome and have an increased prevalence of malignant mucosal neoplasms. Thus, deficiency of telomerase in human patients recapitulates the defects of stem cell functions and tumor predisposition that are observed in late generation telomerase knockout mice.
Short telomeres and high telomerase activity are hallmarks of cancer. As normal or premalignant cells divide, the low or absent telomerase activity results in the eventual erosion of telomeres and activation of cellular checkpoints similar to those provoked by DNA double-strandedbreaks (DSBs) 13 . Like classical DSBs, telomere dysfunction has been shown to induce p53 and associated cellular responses, such as senescence and/or apoptosis 14, 15 . Upon mutational inactivation of p53, cell cycling and cell survival are enhanced in cells with telomere dysfunction, which provides a pro-carcinogenic mutator mechanism characterized by translocations and regional amplifications and deletions 16, 17 . At the same time, continued telomere dysfunction and associated rampant chromosomal instability (even in p53 null cells) appear to constrain full malignant progression of such cancers. For instance, late generation G4-G5 mTERC -/-Ink4a/Arf -/-mice showed significantly reduced lymphoma incidence compared with Ink4a/Arf null mice due to telomere attrition. In another study, more advanced adenomatous lesions in G4 mTERT -/-APC min mice were greatly suppressed in comparison with APC min mice due to significant growth arrest and apoptosis 18, 19 . The observation that telomere dysfunction-induced genomic instability inhibits tumor progression prompts the speculation that the activation of telomerase may enable malignant progression in part by quelling genomic instability to a level compatible with cancer cell viability and/or neutralizing p53-dependent or -independent checkpoint mechanisms.
In order to study whether telomerase reactivation can stop or even reverse ageing of stem cells, and whether telomerase reactivation can promote the tumorigenesis against the backdrop of genomic instability, we generated two inducible murine telomerase alleles. The first one is 4-
Hydroxytamoxifen (4-OHT)-inducible TERT-Estrogen Receptor (mTERT-ER) fusion knock-in allele. In the absence of 4-OHT, mice homozygous for mTERT-ER (designated mTERT ER/ER
) are telomerase activity deficient and sustain same cytogenetic and cellular phenotypes as conventional mTERT or mTERC knockout model. Upon 4-OHT treatment, TERT-ER protein activity can be restored to levels comparable to the native TERT protein 20, 21 . The second allele is a novel inducible TERT knock-in allele containing an intronic LoxP-Stopper-LoxP cassette (LSL-mTERT); upon Cre-mediated excision of LSL, mTERT is re-expressed under endogenous expression control mechanisms 22 .
Protocol
NOTE: All the steps in this protocol have been approved by UT MD Anderson Cancer Center.
Generation of mTERT-ER Allele
1. Introduce knock-in targeting vector containing the ERT2-LBD (Ligand Binding Domain) upstream and in frame with the mTERT genomic sequence (exon 1 through intron 2) and a Lox-pgk-Neo-Lox fragment ( Figure 1A) into mouse ES cells with electroporation. 2. Culture the ES cells in neomycin for 6-10 days. Pick neomycin-resistant clones and expand in 48 well plates. Extract the genomic DNA using a commercial kit and confirm the knock-in allele by southern blot. 3. Inject two ES lines with over 95% normal karyotypes into C57BL/6 blastocysts with a micromanipulation kit under an inverted microscope.
Implant the blastocysts into the uterus of surrogate mothers 23 . Mate the high-grade male chimaeras (70-90%) to C57BL/6 females. 4. Confirm the genotyping of heterozygous mTERT-ERneo animals by southern blot. 5. Mate the heterozygous mTERT-ERneo animals and EIIa-Cre animals to delete the NeoR cassette. Mate the heterozygous animals to C57BL/6 animals for at least three times, and further inter-breed heterozygous mTERT-ER animals to generate homozygosity. Implant the blastocysts into the uterus of surrogate mothers 23 . Mate the high-grade male chimaeras (70-90%) to C57BL/6 females. 4. Confirm the genotyping of heterozygous LSL-mTERT animals by southern blot. 5. Mate the heterozygous animals to C57BL/6 animals for at least three times, and further inter-breed heterozygous LSL-mTERT animals to generate homozygosity.
Generation of LSL-mTERT

Reactivation of Telomerase in mTERT-ER and LSL-mTERT Mice In Vivo
For mTERT-ER 1. Sterilize all the surgical tools before the injection. 2. Anesthetize the mice with isoflurane chamber (4% for induction, 2% for maintaining) in 50% (v/v) oxygen/50% (v/v) dinitrogen monoxide gas mixture. Or anesthetize mice by a ketamine-xylazine mixture (100 mg/kg bodyweight + 10 mg/kg bodyweight). 3. After deep anesthesia is reached, remove the anesthetized animal from the induction chamber, and keep their head inside the tube connected to the isoflurane chamber (2%). 4. Pinch the foot pads of the mice to ensure the animal is deeply anaesthetized. Put ointment on both eyes in order to prevent the eyes from drying out. Wipe the back of the mice with povidone-iodine solution. 5. Inject the slow-releasing 4-OHT pellet with precision trochar (10 G) under the skin of the back and push the pellet all the way to the midline between two shoulders. 6. Seal the incision with wound clip applier and monitor the mice for recovery from anesthesia. Remove the clips 10 days later. Supplemental heat is not necessary because the procedure is finished shortly.
Representative Results
The strategies to generate murine mTERT-ER and LSL-mTERT knock-in alleles were described in Figure 1A and 1B. Specifically, a LoxP-triple Stopper-Neo-LoxP fragment was inserted between exon 1 and exon 2 of mTERT locus to generate LSL-mTERT allele. To generate mTERT-ER allele, ERT2-LBD domain in frame with the mTERT gene was inserted into the N-terminus of exon 1. We showed that when telomerase was transiently reactivated in telomere dysfunction mice by treating them with 4-OHT pellets for 4 weeks, the degenerative phenotype could be ameliorated in multiple organs such as brain (Figure 2A ) and testes ( Figure 2B) . In order to determine the impact of telomerase reactivation on cells cultured in vitro, we isolated neural stem cells (NSCs) from late generation G4 LSL-mTERT and G4 mTERT-ER mice. We showed that when telomerase was reactivated in telomere dysfunctional NSCs, the self-renewal capability of NSCs was greatly increased (Figure 3A) , and in vitro neurogenesis was also significantly enhanced ( Figure 3B) . In order to determine the impact of telomerase reactivation on tumorigenesis in the context of telomere dysfunction, we generated
and Atm -/-mTERT ER/ER (thymic T-cell lymphoma model) late generation cohorts. When telomerase was reactivated by tamoxifen treatment in these mice with injection ( Figure  4A ) or 4-OHT pellets for 8 weeks (Figure 4B) , the tumorigenesis was greatly enhanced in both prostate tumor model ( Figure 4A ) and thymic Tcell lymphoma model ( Figure 4B) . Lastly, we reported the protocols of performing telomere FISH on FFPE mouse brain tissues ( Figure 5 ) and metaphase chromosomes (Figure 5 , inset). Other than studying the function of telomerase in ageing, these two inducible telomerase alleles can also be used to study cancer. Previous studies took advantage of these alleles to explore the role of telomere attrition and telomerase reactivation in shaping the genomes and impacting the biology of T-cell thymic lymphoma 21 and prostate cancer 22 . These two studies showed that telomere dysfunction in late generation
mice provides a mechanism fueling the acquisition of early mutagenic events for tumor initiation, yet preventing progression of fully malignant tumors. When telomerase was reactivated in the context of telomere dysfunction-induced genomic instability, DNA damage checkpoints and rampant chromosomal instability were suppressed , which allowed the full progression of malignant tumors with new biological properties such as bone metastasis of prostate cancer 21 and brain infiltration of thymic lymphoma 21 . Similar phenomena were also observed in other cancer types including colon cancer and pancreatic cancer (personal communications with Drs. Haoqiang Ying, Adam Boutin and Ronald DePinho).
Because TERT-ER protein can be easily toggled between on and off states depending on whether the animals are treated with tamoxifen or vehicle, the tumor models generated by mTERT-ER allele can be utilized to test anti-telomerase therapy. In previous study, tumors generated in G4 Atm -/-mTERT ER/ER animals were released from 4-OHT; upon telomerase depletion, tumors eventually shrank due to the reinstatement of telomere dysfunction-induced checkpoints 21 . However, some of the tumors acquired resistance in response to telomerase extinction by activating an Alternative Lengthening of Telomeres (ALT) mechanism. Further characterization of these ALT+ resistant tumors showed that they have aberrant transcription of genes involved in mitochondrial biology and oxidative defense including a master regulator of mitochondrial synthesis and oxidative defense PGC-1β. Knockdown of PGC-1β or SOD2 (another regulator of oxidative defense) significantly eliminates ALT+ tumor cells while keep telomerase+ tumor cells remain relatively intact 21 .
One limitation of these two knock-in alleles is that they can only afford reactivation of telomerase at endogenous level because they are in the native locus of the telomerase gene. In most human cancers, telomerase is actually overexpressed at a much higher level. In order to enhance the level of telomerase, one modification we can consider is to insert the mTERT-ER construct with a stronger promoter such as PGK (phosphoglycerate kinase) promoter into Rosa26 locus.
In conclusion, these two novel inducible murine telomerase alleles provide unprecedented genetic tools to study the functions of telomerase in ageing and tissue homeostasis as well as the tumor progression, especially under the background of pre-acquired telomere dysfunction-induced genomic instability. The mTERT-ER allele can also be used to study anti-telomerase therapy by crossing into other tumor-prone mouse models.
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